I enjoyed your historical review but let me add to the comments above. I too had gone to Lederle to discuss MTX use in RA in late 70's but at the time they seemed not interested and it was under the Oncology group there. So as Alan Fischman commented we performed an open label prospective trial at UConn and published it in J Rheumatol and a longer term follow up with liver biopsies in Amer J Med. I had also discussed this with Bob Willkens in Seattle who was also studying it and also published around the same time. I received much critcism for suggesting that the hepatic toxicity appeared much less than anticipated from the Scandanavian psoriasis studies. You and Mike deserve the recognition you have received for establishing MTX as our standard of care in RA. Art Weinstein